Shares of GlaxoSmithKline plc (LON:GSK) have received an average rating of “Hold” from the twenty-two brokerages that are covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is GBX 1,715.20 ($22.18).

A number of analysts recently issued reports on the stock. Berenberg Bank upgraded shares of GlaxoSmithKline plc from a “hold” rating to a “buy” rating and raised their price objective for the stock from GBX 1,850 ($23.93) to GBX 1,885 ($24.38) in a report on Friday, May 26th. Liberum Capital restated a “buy” rating and set a GBX 1,900 ($24.57) price objective on shares of GlaxoSmithKline plc in a report on Thursday, July 27th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.57) price objective on shares of GlaxoSmithKline plc and gave the stock a “buy” rating in a report on Wednesday, July 26th. Jefferies Group LLC raised their price objective on shares of GlaxoSmithKline plc from GBX 1,800 ($23.28) to GBX 1,900 ($24.57) and gave the stock a “buy” rating in a report on Friday, June 16th. Finally, Barclays PLC restated an “equal weight” rating and set a GBX 1,550 ($20.05) price objective on shares of GlaxoSmithKline plc in a report on Thursday, July 27th.

Shares of GlaxoSmithKline plc (LON:GSK) traded down 0.23% during midday trading on Wednesday, hitting GBX 1519.50. GlaxoSmithKline plc has a 12-month low of GBX 1,446.50 and a 12-month high of GBX 1,745.56. The stock’s market capitalization is GBX 74.27 billion. The company’s 50 day moving average price is GBX 1,546.43 and its 200-day moving average price is GBX 1,621.42.

The company also recently disclosed a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be given a GBX 19 ($0.25) dividend. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.23%.

COPYRIGHT VIOLATION NOTICE: This article was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/28/glaxosmithkline-plc-gsk-receives-average-rating-of-hold-from-brokerages.html.

In related news, insider Patrick Vallance bought 861 shares of the company’s stock in a transaction on Friday, July 14th. The stock was acquired at an average cost of GBX 1,618 ($20.93) per share, for a total transaction of £13,930.98 ($18,017.30). Also, insider Manvinder Singh Banga bought 2,267 shares of the company’s stock in a transaction on Wednesday, July 26th. The shares were bought at an average price of GBX 1,599 ($20.68) per share, with a total value of £36,249.33 ($46,882.22). Insiders bought 3,151 shares of company stock valued at $5,054,922 over the last 90 days.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.